- Home
- NTRB vs OCUP Comparison
NTRB vs OCUP Comparison
Compare NTRB & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRB
- OCUP
- Stock Information
- Founded
- NTRB 2016
- OCUP 2018
- Country
- NTRB United States
- OCUP United States
- Employees
- NTRB N/A
- OCUP N/A
- Industry
- NTRB Industrial Specialties
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- NTRB Health Care
- OCUP Health Care
- Exchange
- NTRB Nasdaq
- OCUP Nasdaq
- Market Cap
- NTRB 49.2M
- OCUP 53.1M
- IPO Year
- NTRB N/A
- OCUP N/A
- Fundamental
- Price
- NTRB $5.89
- OCUP $1.32
- Analyst Decision
- NTRB
- OCUP Strong Buy
- Analyst Count
- NTRB 0
- OCUP 3
- Target Price
- NTRB N/A
- OCUP $18.67
- AVG Volume (30 Days)
- NTRB 47.2K
- OCUP 86.6K
- Earning Date
- NTRB 09-03-2024
- OCUP 11-11-2024
- Dividend Yield
- NTRB N/A
- OCUP N/A
- EPS Growth
- NTRB N/A
- OCUP N/A
- EPS
- NTRB N/A
- OCUP N/A
- Revenue
- NTRB $1,803,816.00
- OCUP $16,449,000.00
- Revenue This Year
- NTRB N/A
- OCUP N/A
- Revenue Next Year
- NTRB N/A
- OCUP $258.69
- P/E Ratio
- NTRB N/A
- OCUP N/A
- Revenue Growth
- NTRB N/A
- OCUP N/A
- 52 Week Low
- NTRB $1.53
- OCUP $1.15
- 52 Week High
- NTRB $9.60
- OCUP $3.53
- Technical
- Relative Strength Index (RSI)
- NTRB 53.93
- OCUP 48.70
- Support Level
- NTRB $5.70
- OCUP $1.25
- Resistance Level
- NTRB $7.74
- OCUP $1.35
- Average True Range (ATR)
- NTRB 0.67
- OCUP 0.08
- MACD
- NTRB 0.03
- OCUP 0.01
- Stochastic Oscillator
- NTRB 38.53
- OCUP 29.17
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.